EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 28.99 ($0.37) and traded as low as GBX 25 ($0.32). EKF Diagnostics shares last traded at GBX 25 ($0.32), with a volume of 144,190 shares.
EKF Diagnostics Trading Down 1.6 %
The company has a current ratio of 4.59, a quick ratio of 1.77 and a debt-to-equity ratio of 1.78. The firm has a 50-day moving average price of GBX 28.46 and a 200-day moving average price of GBX 28.99. The company has a market capitalization of £113.43 million, a price-to-earnings ratio of 2,500.00 and a beta of 0.57.
About EKF Diagnostics
(
Get Free Report)
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples.
See Also
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
